Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelarabine in Refractory or Recurrent T-ALL and T-LBL
NCT06434467Phase 3Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nelarabine in t-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Composite Complete Response Rate at 2 months. Planned start May 2024; status: not yet recruiting.
02
Drugs
nelarabine
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT06434467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06434467.